Home / Research library / Vitamin C evidence
A clear, evidence-based review of human studies, preclinical research, proposed biological mechanisms, safety considerations, and the limitations of what is currently known about Vitamin C and opioid withdrawal.
Vitamin C (ascorbic acid) is an essential nutrient with well-established physiological functions. Researchers have also investigated whether it may have a role in processes associated with opioid dependence and withdrawal. However, the available human research is limited, much of it is older, and important questions about effectiveness, dosage, formulation, and long-term outcomes remain unanswered.
This page examines the published evidence without treating preliminary findings, historical reports, or proposed mechanisms as proof of clinical effectiveness.
Vitamin C has been investigated in a small number of human and animal studies involving opioid dependence and withdrawal-related outcomes.
One frequently cited human study, published by Evangelou and colleagues in 2000, examined high-dose oral Vitamin C combined with Vitamin E in people with heroin addiction. The authors reported differences in withdrawal-severity categories between the supplemented groups and an inpatient comparison group.
However, the study had significant methodological limitations. It investigated a combination of vitamins, involved relatively small groups, and did not establish that Vitamin C alone was responsible for the reported differences.
Animal studies have also investigated ascorbic acid and morphine tolerance or dependence, but findings in animals cannot establish effectiveness in humans.
The available evidence does not establish Vitamin C as a proven or recommended treatment for opioid withdrawal. It also does not establish an effective or validated consumer dosage, or demonstrate that a particular commercial Vitamin C formulation produces withdrawal-related benefits.
For people experiencing opioid withdrawal or opioid use disorder, qualified medical care and established treatment options should remain central to decision-making.
Research involving Vitamin C and opioid dependence has explored several different questions:
These are distinct research questions. Evidence supporting a biological mechanism does not necessarily demonstrate that a supplement reduces withdrawal symptoms, and evidence from an animal model does not establish effectiveness in people.
The available literature has not established a standardized Vitamin C intervention for opioid withdrawal.
Study: Ascorbic acid (vitamin C) effects on withdrawal syndrome of heroin abusers.
Publication: In Vivo. 2000;14(2):363–366.
Read the original study record on PubMed
This is one of the most frequently cited human studies investigating oral Vitamin C and opioid withdrawal.
The researchers examined whether high-dose oral ascorbic acid, administered alongside Vitamin E, was associated with differences in withdrawal severity among people with heroin addiction.
The study abstract describes three groups:
| Group | Participants | Intervention |
|---|---|---|
| Group A | 30 male inpatients | Oral ascorbic acid plus Vitamin E, alongside conventional medication |
| Group B | 10 male outpatients | Oral ascorbic acid plus Vitamin E |
| Group C | 30 male inpatients | Conventional medication only; comparison group |
According to the published abstract, the vitamin intervention consisted of:
The abstract states that the inpatient vitamin-treated group also received conventional medication, identified as diazepam and an analgesic. The inpatient comparison group received conventional medication only.
Withdrawal severity was assessed using DSM-III criteria, according to the study abstract.
These amounts describe the historical research intervention. They are not recommended doses, a validated treatment schedule, or instructions for readers to follow.
The authors reported the following withdrawal-severity categories:
These are the percentages reported in the study abstract. They should not be interpreted as proof that the vitamin combination caused the differences or as a prediction of the results another person would experience.
The authors concluded that the findings suggested a possible effect and explicitly called for further research to determine dose- and time-dependent effects and clarify the proposed mechanisms.
The study should not be described as a randomized, double-blind, placebo-controlled trial.
The PubMed record identifies it as a clinical trial and includes a single-blind-method indexing term. However, the abstract does not report random allocation or a placebo-control group, and it does not provide enough detail to characterize the blinding procedure fully.
The actual inpatient comparison described in the abstract was between participants receiving the vitamin combination alongside conventional medication and an inpatient group receiving conventional medication only.
The outpatient group did not have a corresponding outpatient comparison group described in the abstract.
The study also has several important limitations:
A 2026 scoping review discussing non-opioid approaches to opioid withdrawal also highlights the small sample, lack of statistical analysis, and concurrent medication use as limitations affecting interpretation of this study.
The Evangelou study documents that a high-dose Vitamin C and Vitamin E combination was investigated in people with heroin addiction and that the authors reported differences in withdrawal-severity categories.
It does not establish:
The study is relevant historical human research, but further research is needed before reliable clinical conclusions can be drawn.
Researchers have also investigated Vitamin C in animal models of morphine tolerance and physical dependence.
These studies can help researchers formulate biological hypotheses, but they are not equivalent to clinical studies involving people.
Study: Megadoses of vitamin C prevent the development of tolerance and physical dependence on morphine in mice.
Read the study on PubMed
This study examined the effects of ascorbic acid in mice receiving morphine.
The researchers reported that ascorbate administered alongside morphine affected the development of tolerance and physical dependence in the animal model.
The study concerns the development of morphine tolerance and dependence in mice. It does not establish that Vitamin C treats existing opioid withdrawal in humans.
Study: Ascorbic acid inhibits development of tolerance and dependence to opiates in mice: Possible glutamatergic or dopaminergic modulation.
Indian Journal of Pharmaceutical Sciences. 2008;70(1):56–60.
Read the study on PubMed
This research investigated the effects of ascorbic acid on morphine tolerance and physical dependence in male mice.
Ascorbic acid was administered during repeated morphine exposure. The researchers then assessed outcomes including analgesic tolerance and naloxone-precipitated withdrawal-related jumping behaviour.
The findings were interpreted in relation to possible glutamatergic and dopaminergic mechanisms.
This remains preclinical research. It does not establish a human treatment protocol, a safe consumer dosage, or the effectiveness of commercial Vitamin C products for opioid withdrawal.
Animal experiments are useful for studying biological processes under controlled conditions. However, differences between animal models and human physiology, drug exposure, metabolism, and withdrawal experiences limit direct translation.
An effect observed in mice does not establish that the same intervention will work, at the same dose or through the same mechanism, in people.
Vitamin C has several established functions in human physiology.
According to the National Institutes of Health Office of Dietary Supplements, Vitamin C:
Vitamin C is also present in relatively high concentrations in certain tissues, including the adrenal glands and brain.
Because Vitamin C participates in antioxidant processes and other biochemical pathways, researchers have investigated its potential relevance to neurological function and opioid-related biological processes.
For example, a review by Margaret Rice examined the regulation and possible neuromodulatory roles of ascorbate in the brain.
Reference: Rice ME. Ascorbate regulation and its neuroprotective role in the brain. Trends in Neurosciences. 2000;23(5):209–216.
Read the review on PubMed
However, the existence of these physiological functions does not demonstrate that increasing Vitamin C intake reduces opioid withdrawal symptoms.
Biological plausibility and clinical effectiveness are different standards of evidence.
The proposed relationships between Vitamin C, oxidative stress, neurotransmitter activity, and withdrawal-related processes require further investigation in humans.
Vitamin C is an essential nutrient, but high supplemental intake can cause adverse effects and may not be appropriate for everyone.
The NIH Office of Dietary Supplements provides the following general reference values:
| Adult intake reference | Amount |
|---|---|
| Recommended dietary allowance, adult men | 90 mg/day |
| Recommended dietary allowance, adult women | 75 mg/day |
| Tolerable upper intake level, adults aged 19 and older | 2,000 mg/day |
These values are general nutritional reference points, not recommended treatments for opioid withdrawal.
The tolerable upper intake level applies to the general population and includes Vitamin C from food and supplements. It is not a recommended supplement target or proof that a particular dose is effective.
The NIH identifies several considerations:
Gastrointestinal effects. High intakes can cause diarrhea, nausea, abdominal cramps, and other gastrointestinal disturbances.
Kidney-related considerations. There are concerns about kidney-stone formation associated with high Vitamin C intake in certain circumstances. Individual risk and medical history matter.
Iron overload. High Vitamin C intake can increase iron absorption. People with hereditary hemochromatosis or other iron-overload conditions should seek appropriate medical guidance.
Individual medical considerations. People with kidney disease, a history of kidney stones, iron-overload conditions, or other relevant medical conditions should discuss supplementation with a qualified healthcare professional.
The NIH also explains that the Tolerable Upper Intake Level does not apply to individuals receiving Vitamin C for medical treatment under physician supervision.
No.
The NIH explains that Vitamin C absorption decreases as oral intake increases. At intakes above approximately 1 gram per day, the absorbed proportion falls to less than 50%, with absorbed, unmetabolized ascorbic acid excreted in urine.
This is an important pharmacokinetic consideration, but it does not establish which intake, if any, would be effective for opioid withdrawal.
There is currently no validated Vitamin C dosing schedule for this purpose that readers should use as a self-treatment protocol.
For more information, see our High-Dose Vitamin C Safety guide.
Research into nutritional approaches should not distract from the established medical options available for opioid use disorder.
The Centers for Disease Control and Prevention identifies buprenorphine, methadone, and naltrexone as FDA-approved medications for opioid use disorder.
Medication treatment is associated with a reduced risk of overdose and overall mortality.
The CDC also states that detoxification alone, without medication treatment for opioid use disorder, is not recommended because of increased risks of return to drug use, overdose, and overdose death.
These treatments have substantially stronger clinical evidence than Vitamin C supplementation for opioid use disorder.
Different medications have different clinical roles, and treatment choices should be made with qualified healthcare professionals.
Further research would be needed to answer several important questions:
Future clinical research would need adequate sample sizes, appropriate comparison groups, transparent intervention methods, clinically meaningful outcome measures, and independent replication.
Vitamin C is an essential nutrient, and researchers have investigated its potential relationship with opioid-related biological processes.
The published literature includes historical human research and animal studies, but the evidence remains limited. The frequently cited 2000 human study examined Vitamin C in combination with Vitamin E and had important methodological limitations. Its findings do not establish the effectiveness of Vitamin C alone or validate a consumer treatment protocol.
The evidence also does not demonstrate that any particular commercial Vitamin C formulation reduces opioid withdrawal symptoms.
For individuals experiencing opioid withdrawal or opioid use disorder, qualified medical care and established treatment options should remain central to decision-making. Vitamin C research should be understood in its proper scientific context, not treated as a substitute for medical treatment.
Our position: We support accurate discussion of published research, transparent reporting of limitations, responsible safety information, and continued scientific investigation. We do not present Vitamin C as a proven treatment for opioid withdrawal.
Evidence-Grading Methodology
High-Dose Vitamin C: Safety, Risks and Considerations
MOUD vs. Detox: Understanding the Difference
When to Seek Medical Care During Withdrawal
Understanding the Opioid Withdrawal Timeline
Editorial note: This page is an educational summary of published research. It is not medical advice, does not provide a treatment protocol, and should not be used to make individual medical decisions. Consult an appropriately qualified healthcare professional for medical guidance.
Opiate Freedom Foundation is affiliated with PowerMade.com, which sells supplements.
Last source review: November 2026.